As Incyte Corporation (INCY) Stock Rose, Baker Bros Advisors LP Decreased Its Position by $192.83 Million

Incyte Corporation (NASDAQ:INCY) LogoInvestors sentiment decreased to 1.23 in 2019 Q2. Its down 0.67, from 1.9 in 2019Q1. It fall, as 39 investors sold INCY shares while 128 reduced holdings. 65 funds opened positions while 140 raised stakes. 188.94 million shares or 0.12% more from 188.70 million shares in 2019Q1 were reported. Conning has 0.01% invested in Incyte Corporation (NASDAQ:INCY). Bp Public Limited Com has invested 0.06% of its portfolio in Incyte Corporation (NASDAQ:INCY). Hm Payson Communication holds 0% or 150 shares in its portfolio. Exane Derivatives holds 199 shares. San Francisco Sentry Invest Gru Inc (Ca) accumulated 367 shares or 0.01% of the stock. Ashford Cap Management Inc has invested 1.72% in Incyte Corporation (NASDAQ:INCY). Fjarde Ap reported 0.05% of its portfolio in Incyte Corporation (NASDAQ:INCY). Allsquare Wealth Mgmt Llc stated it has 133 shares or 0.01% of all its holdings. Nuveen Asset Management Limited Liability Company owns 2.21 million shares for 0.07% of their portfolio. Zurcher Kantonalbank (Zurich Cantonalbank) invested in 38,622 shares. Fred Alger Management invested in 380,999 shares. Interest Ca has invested 0.61% in Incyte Corporation (NASDAQ:INCY). 24,033 were reported by Platinum Investment Mngmt Limited. Cap Guardian reported 0.5% in Incyte Corporation (NASDAQ:INCY). Kansas-based Cognios Limited Company has invested 0.45% in Incyte Corporation (NASDAQ:INCY).

Baker Bros Advisors Lp decreased its stake in Incyte Corporation (INCY) by 6.7% based on its latest 2019Q2 regulatory filing with the SEC. Baker Bros Advisors Lp sold 2.30M shares as the company’s stock rose 7.62% . The hedge fund held 31.98M shares of the commercial physical & biological resarch company at the end of 2019Q2, valued at $2.72B, down from 34.27M at the end of the previous reported quarter. Baker Bros Advisors Lp who had been investing in Incyte Corporation for a number of months, seems to be less bullish one the $16.44B market cap company. The stock increased 0.49% or $0.38 during the last trading session, reaching $76.44. About 894,501 shares traded. Incyte Corporation (NASDAQ:INCY) has risen 23.83% since September 13, 2018 and is uptrending. It has outperformed by 23.83% the S&P500.

Baker Bros Advisors Lp, which manages about $8.20 billion and $14.71 billion US Long portfolio, upped its stake in La Jolla Pharmaceutical Company (NASDAQ:LJPC) by 1.05M shares to 1.56M shares, valued at $14.42M in 2019Q2, according to the filing. It also increased its holding in Tricida Inc. by 166,667 shares in the quarter, for a total of 1.97M shares, and has risen its stake in Neurocrine Biosciences Inc. (NASDAQ:NBIX).

Analysts await Incyte Corporation (NASDAQ:INCY) to report earnings on October, 29. They expect $0.54 EPS, up 170.00 % or $0.34 from last year’s $0.2 per share. INCY’s profit will be $116.15 million for 35.39 P/E if the $0.54 EPS becomes a reality. After $0.56 actual EPS reported by Incyte Corporation for the previous quarter, Wall Street now forecasts -3.57 % negative EPS growth.

More notable recent Incyte Corporation (NASDAQ:INCY) news were published by: Seekingalpha.com which released: “Incyte Q2 Earnings Preview – Seeking Alpha” on July 29, 2019, also Finance.Yahoo.com with their article: “Stocks – Techs Helps S&P Bounce Back From Slump – Yahoo Finance” published on September 04, 2019, Nasdaq.com published: “Commit To Purchase Incyte Corporation At $62.50, Earn 12.3% Using Options – Nasdaq” on April 29, 2019. More interesting news about Incyte Corporation (NASDAQ:INCY) were released by: Nasdaq.com and their article: “Merck’s Keytruda Combination Gets EC Nod for Kidney Cancer – Nasdaq” published on September 05, 2019 as well as Finance.Yahoo.com‘s news article titled: “Is There An Opportunity With Incyte Corporation’s (NASDAQ:INCY) 29% Undervaluation? – Yahoo Finance” with publication date: September 12, 2019.

Incyte Corporation (NASDAQ:INCY) Ratings Coverage

Among 8 analysts covering Incyte (NASDAQ:INCY), 3 have Buy rating, 0 Sell and 5 Hold. Therefore 38% are positive. Incyte has $11100 highest and $7500 lowest target. $91.13’s average target is 19.22% above currents $76.44 stock price. Incyte had 15 analyst reports since April 2, 2019 according to SRatingsIntel. The company was maintained on Wednesday, July 31 by Nomura. The firm earned “Equal-Weight” rating on Friday, May 3 by Barclays Capital. JMP Securities reinitiated Incyte Corporation (NASDAQ:INCY) rating on Thursday, September 5. JMP Securities has “Market Outperform” rating and $10700 target. Oppenheimer upgraded Incyte Corporation (NASDAQ:INCY) on Thursday, September 5 to “Outperform” rating. Morgan Stanley reinitiated the shares of INCY in report on Thursday, September 5 with “Equal-Weight” rating. The stock of Incyte Corporation (NASDAQ:INCY) has “Equal-Weight” rating given on Wednesday, July 31 by Morgan Stanley.

Incyte Corporation (NASDAQ:INCY) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.